Vico Therapeutics
@vicotx.bsky.social
Pioneering RNA-based science to target the root cause of rare genetic neurological diseases
Piotr Puta, PhD, Director of Oligonucleotide Chemistry, will be attending the Drug Discovery Strategic Summit in Amsterdam. At Vico, we are targeting the genetic root causes of complex neurological diseases like Huntington's and spinocerebellar ataxias. Let's connect if you will be at the Summit!
November 12, 2025 at 1:06 PM
Piotr Puta, PhD, Director of Oligonucleotide Chemistry, will be attending the Drug Discovery Strategic Summit in Amsterdam. At Vico, we are targeting the genetic root causes of complex neurological diseases like Huntington's and spinocerebellar ataxias. Let's connect if you will be at the Summit!
Vico CEO Micah Mackison and Vice President, Corporate Business Development and Strategy Prarthana Khana, PhD, will be in London during London Life Science Week, November 16-21, and would love to connect!
Please reach out to set up a time to meet!
Please reach out to set up a time to meet!
November 10, 2025 at 3:28 PM
Vico CEO Micah Mackison and Vice President, Corporate Business Development and Strategy Prarthana Khana, PhD, will be in London during London Life Science Week, November 16-21, and would love to connect!
Please reach out to set up a time to meet!
Please reach out to set up a time to meet!
We just wrapped up an incredible few days at BIO-Europe!
Our VP of Corporate Business Development & Strategy, Prarthana Khanna, PhD, and Senior Scientist Sonia Najas Sales, PhD, have been discussing how Vico is advancing RNA-modulating therapies for severe neurodegenerative and genetic diseases.
Our VP of Corporate Business Development & Strategy, Prarthana Khanna, PhD, and Senior Scientist Sonia Najas Sales, PhD, have been discussing how Vico is advancing RNA-modulating therapies for severe neurodegenerative and genetic diseases.
November 7, 2025 at 5:05 PM
We just wrapped up an incredible few days at BIO-Europe!
Our VP of Corporate Business Development & Strategy, Prarthana Khanna, PhD, and Senior Scientist Sonia Najas Sales, PhD, have been discussing how Vico is advancing RNA-modulating therapies for severe neurodegenerative and genetic diseases.
Our VP of Corporate Business Development & Strategy, Prarthana Khanna, PhD, and Senior Scientist Sonia Najas Sales, PhD, have been discussing how Vico is advancing RNA-modulating therapies for severe neurodegenerative and genetic diseases.
Thank you Rarecast for featuring Prarthana Khanna, VP, Corporate Business Development and Strategy, in this conversation on Huntington's disease, Vico's ASO therapy in development and how our approach could extend beyond Huntington’s to a broader group of polyglutamine diseases.
bit.ly/43JTzrq
bit.ly/43JTzrq
October 31, 2025 at 3:50 PM
Thank you Rarecast for featuring Prarthana Khanna, VP, Corporate Business Development and Strategy, in this conversation on Huntington's disease, Vico's ASO therapy in development and how our approach could extend beyond Huntington’s to a broader group of polyglutamine diseases.
bit.ly/43JTzrq
bit.ly/43JTzrq
At Vico, we go beyond symptoms. VO659 targets the genetic source of disease with precision, aiming for true disease-modifying effects and hope for patients with complex neurological conditions. vicotx.com/our-science/
October 30, 2025 at 2:16 PM
At Vico, we go beyond symptoms. VO659 targets the genetic source of disease with precision, aiming for true disease-modifying effects and hope for patients with complex neurological conditions. vicotx.com/our-science/
Heading to #BIOEurope in Vienna next week? Let’s connect!
Vico Therapeutics is advancing RNA-modulating therapies for severe neurodegenerative and genetic diseases, including our lead ASO VO659 in Phase 1/2 for Huntington’s and SCA.
Vico Therapeutics is advancing RNA-modulating therapies for severe neurodegenerative and genetic diseases, including our lead ASO VO659 in Phase 1/2 for Huntington’s and SCA.
October 29, 2025 at 6:42 PM
Heading to #BIOEurope in Vienna next week? Let’s connect!
Vico Therapeutics is advancing RNA-modulating therapies for severe neurodegenerative and genetic diseases, including our lead ASO VO659 in Phase 1/2 for Huntington’s and SCA.
Vico Therapeutics is advancing RNA-modulating therapies for severe neurodegenerative and genetic diseases, including our lead ASO VO659 in Phase 1/2 for Huntington’s and SCA.
That’s a wrap on #OTS2025 in Budapest!
At Vico, we’re advancing allele-preferential ASO therapies that target the root causes of neurological diseases like Huntington’s, SCA, and Rett syndrome—pushing RNA science forward for patients who need it most
At Vico, we’re advancing allele-preferential ASO therapies that target the root causes of neurological diseases like Huntington’s, SCA, and Rett syndrome—pushing RNA science forward for patients who need it most
October 28, 2025 at 1:36 PM
That’s a wrap on #OTS2025 in Budapest!
At Vico, we’re advancing allele-preferential ASO therapies that target the root causes of neurological diseases like Huntington’s, SCA, and Rett syndrome—pushing RNA science forward for patients who need it most
At Vico, we’re advancing allele-preferential ASO therapies that target the root causes of neurological diseases like Huntington’s, SCA, and Rett syndrome—pushing RNA science forward for patients who need it most
Vico CEO Micah Mackison and Vice President, Corporate Business Development and Strategy Prarthana Khana, PhD, will be in London during London Life Science Week, November 16-21, and would love to connect if you will be there.
Please reach out to set up a time to meet!
Please reach out to set up a time to meet!
October 21, 2025 at 1:18 PM
Vico CEO Micah Mackison and Vice President, Corporate Business Development and Strategy Prarthana Khana, PhD, will be in London during London Life Science Week, November 16-21, and would love to connect if you will be there.
Please reach out to set up a time to meet!
Please reach out to set up a time to meet!
Heading to #BIOEurope in Vienna! Our VP, Prarthana Khanna, PhD, and Senior Scientist Sonia Najas Sales will share how Vico’s ASO platform targets the root causes of Huntington’s & spinocerebellar ataxias, regardless of mutation type. Let’s connect!
October 15, 2025 at 7:06 PM
Heading to #BIOEurope in Vienna! Our VP, Prarthana Khanna, PhD, and Senior Scientist Sonia Najas Sales will share how Vico’s ASO platform targets the root causes of Huntington’s & spinocerebellar ataxias, regardless of mutation type. Let’s connect!
Heading to #BIOEurope in Vienna! Our VP, Prarthana Khanna, PhD, and Senior Scientist Sonia Najas Sales will share how Vico’s ASO platform targets the root causes of Huntington’s & spinocerebellar ataxias, regardless of mutation type. Let’s connect! #BIOEurope
October 14, 2025 at 6:56 AM
Heading to #BIOEurope in Vienna! Our VP, Prarthana Khanna, PhD, and Senior Scientist Sonia Najas Sales will share how Vico’s ASO platform targets the root causes of Huntington’s & spinocerebellar ataxias, regardless of mutation type. Let’s connect! #BIOEurope
In Budapest for #OTS2025! Vico is advancing ASO therapies that target disease at its genetic source — including VO659, designed to address CAG repeat expansion disorders such as HD & SCAs.
October 13, 2025 at 2:41 PM
In Budapest for #OTS2025! Vico is advancing ASO therapies that target disease at its genetic source — including VO659, designed to address CAG repeat expansion disorders such as HD & SCAs.
The Vico team is in Nashville for the #HDClinicalResearchCongress!
We’ll share updates on VO659, our CAG repeat–targeting ASO, the first in clinical development with potential to treat all polyQ diseases.
Let’s connect at the meeting!
We’ll share updates on VO659, our CAG repeat–targeting ASO, the first in clinical development with potential to treat all polyQ diseases.
Let’s connect at the meeting!
October 10, 2025 at 5:42 PM
The Vico team is in Nashville for the #HDClinicalResearchCongress!
We’ll share updates on VO659, our CAG repeat–targeting ASO, the first in clinical development with potential to treat all polyQ diseases.
Let’s connect at the meeting!
We’ll share updates on VO659, our CAG repeat–targeting ASO, the first in clinical development with potential to treat all polyQ diseases.
Let’s connect at the meeting!
Our new website is live! www.vicotx.com. Vico is rewriting what’s possible in RNA-targeted therapies—bringing hope to those with severe neurological diseases. Bold science. Clear mission. Urgent focus.
October 6, 2025 at 2:42 PM
Our new website is live! www.vicotx.com. Vico is rewriting what’s possible in RNA-targeted therapies—bringing hope to those with severe neurological diseases. Bold science. Clear mission. Urgent focus.
Huntington’s disease is a lifelong challenge that impacts movement, cognition and mental health. Over time, symptoms worsen and full-time care is often needed. At Vico, we’re working to bring new hope to patients and their families. vicotx.com/patients-and... #HDSA #LetsTalkAboutHD
September 22, 2025 at 3:30 PM
Huntington’s disease is a lifelong challenge that impacts movement, cognition and mental health. Over time, symptoms worsen and full-time care is often needed. At Vico, we’re working to bring new hope to patients and their families. vicotx.com/patients-and... #HDSA #LetsTalkAboutHD
Grateful to the BioHub podcast for inviting CEO @Micah Mackison to share how his journey in biotech shapes Vico’s vision.
We’re driven by bold science and inspired people, all with one purpose to change outcomes for patients facing neurodegenerative disease. open.spotify.com/episode/0Vox...
We’re driven by bold science and inspired people, all with one purpose to change outcomes for patients facing neurodegenerative disease. open.spotify.com/episode/0Vox...
September 16, 2025 at 1:46 PM
Grateful to the BioHub podcast for inviting CEO @Micah Mackison to share how his journey in biotech shapes Vico’s vision.
We’re driven by bold science and inspired people, all with one purpose to change outcomes for patients facing neurodegenerative disease. open.spotify.com/episode/0Vox...
We’re driven by bold science and inspired people, all with one purpose to change outcomes for patients facing neurodegenerative disease. open.spotify.com/episode/0Vox...
Vico is proud to join Huntington's Disease Society of America in celebrating Founders Day on Thursday, Sept 18, a 24-hour day of giving dedicated to founder Marjorie Guthrie. Her vision united families, clinicians and scientists to fuel progress. Learn more: app.dvforms.net/api/dv/dwl518
September 12, 2025 at 2:32 PM
Vico is proud to join Huntington's Disease Society of America in celebrating Founders Day on Thursday, Sept 18, a 24-hour day of giving dedicated to founder Marjorie Guthrie. Her vision united families, clinicians and scientists to fuel progress. Learn more: app.dvforms.net/api/dv/dwl518
At the Rett Genetic Medicines Summit 2025, our CSO, Nicole Datson, PhD, presented, “Development of RNA editing antisense oligonucleotides for the treatment of Rett syndrome.” By aiming to restore or enhance MECP2 function, VO366 represents a potential new approach to transform care for patients.
September 11, 2025 at 2:59 PM
At the Rett Genetic Medicines Summit 2025, our CSO, Nicole Datson, PhD, presented, “Development of RNA editing antisense oligonucleotides for the treatment of Rett syndrome.” By aiming to restore or enhance MECP2 function, VO366 represents a potential new approach to transform care for patients.
CEO Micah Mackison and VP, Head of Corporate Business Development & Strategy Prarthana Khanna will be attending the Bank of America Trailblazers Private Company Conference in Boston on Wednesday, Sept 17. We’d love to connect if are planning to be there. Please reach out to set up a time to meet!
September 9, 2025 at 3:31 PM
CEO Micah Mackison and VP, Head of Corporate Business Development & Strategy Prarthana Khanna will be attending the Bank of America Trailblazers Private Company Conference in Boston on Wednesday, Sept 17. We’d love to connect if are planning to be there. Please reach out to set up a time to meet!
We’re not just treating symptoms—we’re targeting the genetic root of neurodegenerative disease. At Vico, we’re developing ASO therapies for conditions like Huntington’s with the potential to truly modify disease. Learn more: vicotx.com/our-science/ #HuntingtonsDisease #ASOtherapy #HDSA
September 5, 2025 at 1:48 PM
We’re not just treating symptoms—we’re targeting the genetic root of neurodegenerative disease. At Vico, we’re developing ASO therapies for conditions like Huntington’s with the potential to truly modify disease. Learn more: vicotx.com/our-science/ #HuntingtonsDisease #ASOtherapy #HDSA
Behind every breakthrough is a team. Today we spotlight Suzanne Brakenhoff-Bijl, Sr. Manager R&D Ops & HSE Coordinator—driving science forward while ensuring safety & excellence. Grateful for your dedication, Suzanne!
September 3, 2025 at 11:37 AM
Behind every breakthrough is a team. Today we spotlight Suzanne Brakenhoff-Bijl, Sr. Manager R&D Ops & HSE Coordinator—driving science forward while ensuring safety & excellence. Grateful for your dedication, Suzanne!
Vico CEO @Micah Mackison will be in New York City next week for the Cantor Global Healthcare Conference meeting and looking forward to connecting with the investment community. If you are going to be there, we welcome the chance to connect.
August 29, 2025 at 2:59 PM
Vico CEO @Micah Mackison will be in New York City next week for the Cantor Global Healthcare Conference meeting and looking forward to connecting with the investment community. If you are going to be there, we welcome the chance to connect.
At Vico, we’re going to the source: targeting the CAG repeat expansion driving Huntington’s & other polyQ diseases. Our lead ASO, VO659, aims to treat 9 conditions with one molecule, a bold, differentiated approach to rare neurology.
August 28, 2025 at 2:15 PM
At Vico, we’re going to the source: targeting the CAG repeat expansion driving Huntington’s & other polyQ diseases. Our lead ASO, VO659, aims to treat 9 conditions with one molecule, a bold, differentiated approach to rare neurology.
Paul Koevoets is speaking today at the 4th Annual Oligonucleotide CMC & Analytical Development Summit on impurity profiling of VO659 and how we are advancing allele-preferential ASO therapies for Huntington’s & SCAs
August 26, 2025 at 1:24 PM
Paul Koevoets is speaking today at the 4th Annual Oligonucleotide CMC & Analytical Development Summit on impurity profiling of VO659 and how we are advancing allele-preferential ASO therapies for Huntington’s & SCAs
What are ASOs? Antisense Oligonucleotides are synthetic molecules that bind to RNA targets, blocking harmful proteins and enabling precise gene modulation. At Vico, our VO659 ASO targets Huntington's disease and SCAs at their genetic source. vicotx.com/our-science/ #ASOs #HuntingtonsDisease
August 12, 2025 at 2:16 PM
What are ASOs? Antisense Oligonucleotides are synthetic molecules that bind to RNA targets, blocking harmful proteins and enabling precise gene modulation. At Vico, our VO659 ASO targets Huntington's disease and SCAs at their genetic source. vicotx.com/our-science/ #ASOs #HuntingtonsDisease
Thrilled to welcome Piotri Putaj as Director, Oligonucleotide Chemistry at Vico! His RNA expertise strengthens our mission to advance allele-preferential ASO therapies for rare genetic neurological diseases. #ASO
August 7, 2025 at 4:20 PM
Thrilled to welcome Piotri Putaj as Director, Oligonucleotide Chemistry at Vico! His RNA expertise strengthens our mission to advance allele-preferential ASO therapies for rare genetic neurological diseases. #ASO